AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Income from Continuing Operations came in at 29802000.0 in Q1 2026, down 12.61% year-on-year from 34101951.31 in Q1 2025, and down 12.61% quarter-over-quarter from 26465000.0 in Q1 2025.
AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 6 years of Income from Continuing Operations data on file, last reported at 61067000.0 in Q3 2025.
- For the quarter ending Q3 2025, Income from Continuing Operations fell 129.03% year-over-year to 61067000.0; the trailing twelve-month figure through Sep 2025 stood at 154276000.0 (down 20.36% YoY), and the FY2024 full-year result was 148049000.0, down 267.35% from the prior year.
- Income from Continuing Operations eased to 29802000.0 in Q1 2026 per ATAI's latest filing, from 26465000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 26465000.0 in Q1 2025 and bottomed at 29802000.0 in Q1 2026.
- A 5-year average of 30429526.32 and a median of 31843000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 842.61% in 2021 and jumped 231.22% in 2023, its largest moves.
- Tracing ATAI's Income from Continuing Operations over 5 years: stood at 49296000.0 in 2021, then advanced by 18.3% to 40276000.0 in 2022, then soared by 53.45% to 18748000.0 in 2023, then sank by 107.97% to 38991000.0 in 2024, then sank by 56.62% to 61067000.0 in 2025.
- Business Quant data shows ATAI's Income from Continuing Operations at 61067000.0 in Q3 2025, 27753000.0 in Q2 2025, and 26465000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | -61.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.80 Mn |
| Sep 30, 2025 | -61.07 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Dec 31, 2024 | -38.99 Mn |
| Sep 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -57.10 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -18.75 Mn |
| Sep 30, 2023 | 43.61 Mn |
| Jun 30, 2023 | -31.84 Mn |
| Mar 31, 2023 | -33.36 Mn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -33.23 Mn |
| Jun 30, 2022 | -30.86 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -49.30 Mn |
| Sep 30, 2021 | -26.87 Mn |
| Jun 30, 2021 | -67.36 Mn |